What can we do today to build a healthier tomorrow for Central and Eastern Europeans? Access to healthcare, affordable medicines and digitisation are some of the answers that we will be presenting on Friday, 21 April. Hear from European healthcare experts like Kostas Deligiannis, CEO for Eastern Europe, GE Healthcare; Arjon van Hengel, Deputy Head of Unit, Health Innovations and Ecosystems, Directorate-General for Research and Innovation, European Commission; Cyril Schiever, Senior Vice-President and President, Mid-Europe Region, MSD and Anca Toma, Executive Director, European Patients’ Forum; who will be discussing how to achieve affordability of healthcare in the region - register today.
Reaching accessible healthcare across Europe
What can we do today to build a healthier tomorrow for Central and Eastern Europeans? Access to healthcare, affordable medicines and digitisation are some of the answers that we will be presenting on Friday, 21 April. Hear from European healthcare experts like Kostas Deligiannis, CEO for Eastern Europe, GE Healthcare; Arjon van Hengel, Deputy Head of Unit, Health Innovations and Ecosystems, Directorate-General for Research and Innovation, European Commission; Cyril Schiever, Senior Vice-President and President, Mid-Europe Region, MSD and Anca Toma, Executive Director, European Patients’ Forum; who will be discussing how to achieve affordability of healthcare in the region - register today.

Related items
:focal())
Healthcare, competitiveness, innovation and simplification
Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation.
The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment.
The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains.
:focal())
Strengthening EU competitiveness through an adaptive MDR/IVDR framework
:focal())
A global approach to strengthening Europe’s biotechnology ecosystem
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.